Our Pipeline
Three core assets in registrational trials for ophthalmic and neuro-ophthalmic diseases
Our late-stage pipeline has the potential to shift treatment paradigms and make a real difference in patients’ lives.
Candidate
Phase 1
Phase 2
Phase 3
Neuro-Ophthalmology
Privosegtor
Multiple Sclerosis Relapses
Neuro-Ophthalmology
Candidate:
Privosegtor
Candidate
Phase 1
Phase 2
Phase 3
Candidate:
Privosegtor
Candidate
Phase 1
Phase 2
Phase 3
Candidate:
Privosegtor
Candidate
Phase 1
Phase 2
Phase 3
Multiple Sclerosis Relapses
Ophthalmology
Privosegtor and Licaminlimab are investigational drugs and their safety or efficacy has not been established and it has not received regulatory approval for commercial use in any country.
Rethinking Ophthalmology to Save Sight and Improve Eye Care
We are rethinking what’s possible for patients and pursuing visionary innovations that go beyond incremental changes and challenges current convention. Our team is relentlessly focused on advancing our highly differentiated late-stage pipeline which has the potential to transform patients’ lives.
Our potential to transform patients’ lives through visionary innovation
